It is currently Sun Dec 21, 2014 9:11 pm

News News of Tysabri (Antegren or Natalizumab)

Site map of Tysabri (Antegren or Natalizumab) » Forum : Tysabri (Antegren or Natalizumab)

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Monotherapy Question

Has anyone heard how much time needs to lapse between immunosuppressive treatments and Tysabri? I'm going to have one more Novantrone infusion next week.
Read more : Monotherapy Question | Views : 1431 | Replies : 1


Bring back Harry Z

Dear all,

Harry, I was just trying to wind you up. You know me well enough by now. I had no idea that your surname really began with Z.

Arron - sorry if this caused you any problems. I never ever though that the post would be taken seriously.

My latest survey shows that 97% want the ban on Harry Z to be lifted. Welcome back Harry Z.


Ian
Read more : Bring back Harry Z | Views : 1960 | Replies : 5


Ban Harry Z

This is not my idea, but I have received a huge number of PMs asking me to raise this with Arron.

My recent survey of users of this site showed that of the 654 who voted, 86% want Harry Z banned from the thisisms site.

Harry is a menace. I have received a number of e-mails saying that Harry Z holds a substantial amount of stock in Teva, which accounts for his unrelenting attacks on ...
Read more : Ban Harry Z | Views : 2085 | Replies : 5


testing for PML

Hi -

I've been reading through all the newly shared data and opinions on Tysabri and I have a question that maybe someone can answer. Does anyone know how the testing for PML is done? One description I read said they are taking "serial measurements of JC viral load" and I'm wondering just how those measurements are obtained.

Thanks,
Arcee
Read more : testing for PML | Views : 1219 | Replies : 0


TYSABRI® Two-Year Phase III Published in New England Journal

http://www.elan.com/news/print_full.asp?ID=824216

1 March 2006
TYSABRI® Two-Year Phase III Multiple Sclerosis Clinical Trial Results and Safety Evaluation Published in New England Journal of Medicine; TYSABRI Currently Under Review with U.S. and European Regulatory Authorities
CAMBRIDGE, Mass. and DUBLIN, Ireland, Mar 01, 2006 (BUSINESS WIRE) -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that two-year results from the two Phase III clinical trials evaluating TYSABRI(R) (natalizumab) ...
Read more : TYSABRI® Two-Year Phase III Published in New England Journal | Views : 2616 | Replies : 4


EMail to FDA/AC ie TEVA

.
I found this interesting post today on an messageboard.

" EMail to FDA/AC ie TEVA

by: uvauncduke 02/28/06 - This post has 86 recommendations

Dear Dr. Mosaddeghs:

I understand you represent CDER/FDA in the upcoming Peripheral and Central Nervous System Drugs Advisory Committee meeting regarding the multiple sclerosis drug Tysabri scheduled for March 7th and 8th.

As a physician I have both professional and personal contacts with patients stricken with multiple sclerosis. I greatly ...
Read more : EMail to FDA/AC ie TEVA | Views : 2957 | Replies : 14


New abstracts on Tysabri from AAN meeting

Check it out... lots of tantalizing information here.

http://www.thisisms.com/modules.php?nam ... le&sid=255
Read more : New abstracts on Tysabri from AAN meeting | Views : 1346 | Replies : 1


article from Boston globe about Tysabri

Judge orders Biogen to turn over MRIs in Tysabri case
By Jeffrey Krasner, Globe Staff | February 25, 2006

A Middlesex Superior Court judge yesterday ordered Biogen Idec Inc. to turn over MRI images of Anita Smith, a Colorado woman who died of a rare disease while participating in a clinical trial of Tysabri, the company's multiple sclerosis drug.

Smith's widower, Walter Smith of Colorado Springs, Colo., last year sued the Cambridge biotechnology company and ...
Read more : article from Boston globe about Tysabri | Views : 1314 | Replies : 1


Tysabri article from today's WSJ

Tricky FDA Debate:
Should a Risky Drug
Be Approved Again?

By ANNA WILDE MATHEWS and SYLVIA PAGÁN WESTPHAL
February 24, 2006; Page B1

Next month, Food and Drug Administration advisers will take up one of the most difficult questions the agency ever faces: Should a promising drug that carries a known and deadly side effect still be allowed on the market?

Tysabri was seen as a life-changing drug for the nation's 400,000 multiple-sclerosis patients and ...
Read more : Tysabri article from today's WSJ | Views : 2442 | Replies : 10


Another Tysabri article

Dear all,

Another Tysabri article, but it raises issues that have been discussed before - what sort of patients are enrolled into trials. Of course, the drug makers would prefer those with mild disease / early disease, then they could show that the patients didn't progress / had minimal relapses or inflammatory activity. It's a bit like some of the selective schools in the UK who only take on the brightest kids and then get ...
Read more : Another Tysabri article | Views : 2056 | Replies : 6


 

Login  •  Register


Statistics

Total posts 222332 • Total topics 23091 • Total members 14618


Contact us | Terms of Service